• Health Systems

Rethink cancer screening for your health system or provider network 

Screen for many of the deadliest cancers with a single blood draw.¹

Learn More

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.

Leading organizations at the forefront of cancer screening with the Galleri® test

• “ As a complement to current cancer screening programs, we believe the novel Galleri test offers an innovative way to assist with early cancer detection. ”

• “ As a leader in cancer prevention and care, this is an opportunity to be at the forefront of a new age of cancer screening ”

• “ We will be able to offer veterans state-of-the-art detection for many different types of cancer, most of which don’t have guideline recommended screening. ”

• “ We found Galleri to be a relatively low investment for our health system compared to the impact it could have for our patients. ”

• “ Multi-cancer early detection lined up with Mercy’s strategy of being proactive, predictive, and personalized. ”

• “ For my entire career, patients have asked me: ‘Doctor, don’t you just have a blood test for cancer?’ For the first time, I can say: ‘yes we do ”

1 / 6

Why is early detection important?

Around 70% of cancer-related deaths are caused by cancers with no recommended screening tests.^2,3*

When diagnosed early, the 5-year cancer-related survival rate is 4 times higher than when diagnosed in later stages.^4†

The Galleri test could provide a 53% reduction in stage IV diagnoses with annual testing added to usual care between ages 50 and 79 years (based on modeled data).⁵

Late-stage cancer can cost up to 7 times more than early-stage cancer.⁶

*Assumes screening is available for all prostate, breast, cervical, and colorectal cancer cases and 43% of lung cancer cases (based on the estimated proportion of lung cancers that occur in screen-eligible individuals older than 40 years).

†“Early/Localized” includes invasive localized tumors that have not spread beyond the organ of origin; “Late/Metastasized” includes invasive cancers that have metastasized beyond the organ of origin to other parts of the body.

How the Galleri test works

Cancers growing in the body shed DNA into the bloodstream.^1,7,8 Although there are many types of cancer, the DNA fragments act like a unique “fingerprint” of cancer. The Galleri test screens for many of the deadliest cancers before they become symptomatic,^1,9 including some without recommended screening tests.^1,3 The Galleri test results provide direction to your healthcare provider on the cancer’s origin and can help guide next steps for diagnosis.⁹

Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests.

Play Video Cookie notice ⓘ

“Multi-cancer early detection tests should be added to routine cancer screening, and that's what we're doing here at Adventist Health.”

Dr. Tyler Kang

Medical Oncologist and Medical Director

Adventist Health Martin O'Neill Cancer Center

Play Video Cookie notice ⓘ

The Galleri test could result in a 26% reduction in 5-year cancer-related mortality when added to usual care (based on modeled data)¹⁰

97% patient satisfaction with the Galleri test^11‡
 

‡The PATHFINDER study was conducted with an earlier version of the Galleri test. Participants responding satisfied, very satisfied, or extremely satisfied to the following question: “Taking all things into account, how satisfied or dissatisfied are you with the multi-cancer early detection test?”

Ongoing clinical evidence program backed by 380,000+ participants

The GRAIL clinical evidence program includes more than 380,000 participants in completed or ongoing studies. To support and validate our technology, studies are being performed at leading health systems and community and academic medical centers in the US and UK.

See the clinical data

Learn more about the Galleri test

1 / 8

• Case Study

  

  Lessons from Community Health Network’s multi-cancer early detection testing program

  Read on
• Video

  

  How Leading Health Systems Enable their PCPs to Screen for Cancer Early

  Watch the webinar
• Report

  

  White Paper: 4 MCED Adoption Models for Health Systems

  Read on
• Report

  

  Case Study: How Health Systems, PCPs, and Patients are Benefitting from Galleri

  Read on
• CME

  

  

  The Cancer Check-Up: Early Detection Using Multi-Cancer Screening

  Read on
• News

  

  Innovative New Blood Tests Could Detect Cancers Early

  Read on
• Video

  

  This New Blood Test Could Change the Way We Detect Cancer Forever

  Watch now
• News

  

  Galleri Named to TIME's Best Inventions of 2022

  Read on

Learn more

To connect with GRAIL, please fill out this form.

If you are a concierge, private, or group practice provider, complete this form instead.

1. What describes you best?

   I represent a Health System or Provider Network

2. What are you looking for?

   I'd like to speak with someone

3. Fill in the form

   Health System or Provider Network

   If you are a concierge, private, or group practice provider, complete this form instead.

   First name

   Last name

   Health system or Provider network name

   Title

   DepartmentPlease select an optionExecutive Leadership TeamHuman ResourcesLab / PharmacyOncologyPopulation HealthPrecision MedicinePrimary / Ambulatory CareStrategy / InnovationOther

   Work email address

   Phone number

   StateSelect a StateAlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareDistrict of ColumbiaFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWest VirginiaWisconsinWyoming

   Zip code

   Submit

   By submitting this form, you agree to GRAIL’s use of this information to contact you, including for marketing purposes. Please do not include any sensitive or confidential information, including health information. For more information, please refer to our privacy notice.

Important Safety Information

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

Laboratory / Test Information

The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed — and its performance characteristics were determined — by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

References

1. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-77. doi: 10.1016/j.annonc.2021.05.806
2. American Cancer Society. Cancer facts & figures 2022. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html [GRAIL, Inc. Data on file: GA-2021-0065]
3. US Preventive Services Task Force. A,B,C grade recommendations, cancer, screening [cited 2023 Oct 23]. https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results 
4. [GRAIL, Inc. Data on file: GA-2021-0004]
5. Tafazzoli A, Ramsey SD, Shaul A, et al. The potential value-based price of a multi-cancer early detection genomic blood test to complement current single cancer screening in the USA. PharmacoEconomics. 2022;40(11):1107-17. doi: 10.1007/s40273-022-01181-3
6. Reddy SR, Broder MS, Chang E, et al. Cost of cancer management by stage at diagnosis among Medicare beneficiaries. Curr Med Res Opin. 2022;38(8):1285-94. doi: 10.1080/03007995.2022.2047536
7. Liu MC, Oxnard GR, Klein EA, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31(6):745-59. doi: 10.1016/j.annonc.2020.02.011
8. Thierry AR, El Messaoudi S, Gahan PB, et al. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 2016;35:347–76. doi: 10.1007/s10555-016-9629-x
9. Schrag D, Beer TM, McDonnell CH, et al. Blood-based tests for multi-cancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402:1251-1260. doi: 10.1016/S0140-6736(23)01700-2
10. Hubbell E, Clarke CA, Aravanis AM, et al. Modeled reductions in late-stage cancer with a multi-cancer early detection test. Cancer Epidemiol Biomarkers Prev. 2021;30(3):460-8. doi: 10.1158/1055-9965.EPI-20-1134
11. Nadauld L, McDonnell CH, Dilaveri CA, et al. Psychosocial impact associated with a multicancer early detection test (PATHFINDER): a prospective, multicentre, cohort study. Lancet Oncol. 2025;26(2):165-74. doi: 10.1016/S1470-2045(24)00645-4